HRP20050149B1 - Formulacija aripiprazol kompleksa i postupak - Google Patents
Formulacija aripiprazol kompleksa i postupakInfo
- Publication number
- HRP20050149B1 HRP20050149B1 HRP20050149AA HRP20050149A HRP20050149B1 HR P20050149 B1 HRP20050149 B1 HR P20050149B1 HR P20050149A A HRP20050149A A HR P20050149AA HR P20050149 A HRP20050149 A HR P20050149A HR P20050149 B1 HRP20050149 B1 HR P20050149B1
- Authority
- HR
- Croatia
- Prior art keywords
- aripiprazole
- cyclodextrin
- site
- formulation
- complex formulation
- Prior art date
Links
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004372 aripiprazole Drugs 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000002347 injection Methods 0.000 abstract 3
- 239000007924 injection Substances 0.000 abstract 3
- 229920000858 Cyclodextrin Polymers 0.000 abstract 2
- 230000007794 irritation Effects 0.000 abstract 2
- 230000003387 muscular Effects 0.000 abstract 2
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- -1 sulfobutyl Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Pružena je formulacija aripiprazola koja uključuje antipsihotičko sredstvo aripiprazol u obliku inkluzijskog kompleksa u Ăź-ciklodekstrinu, preferirano sulfobutil eter-Ăź-ciklodekstrin (SBECD) koji u otopini za injekcije proizvodi reverzibilnu općenito minimalnu do blagu iritaciju na mjestu muskularne injekcije. Također je pružen postupak za minimiziranje iritacije uzrokovane apiprazolom na mjestu muskularne injekcije i postupak za liječenje šizofrenije primjenom gore opisane formulacije.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40471302P | 2002-08-20 | 2002-08-20 | |
PCT/US2003/025573 WO2004017897A2 (en) | 2002-08-20 | 2003-08-14 | Aripiprazole complex formulation and method |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20050149A2 HRP20050149A2 (en) | 2005-10-31 |
HRP20050149B1 true HRP20050149B1 (hr) | 2014-09-12 |
Family
ID=31946748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20050149AA HRP20050149B1 (hr) | 2002-08-20 | 2005-02-16 | Formulacija aripiprazol kompleksa i postupak |
Country Status (32)
Country | Link |
---|---|
US (8) | US7115587B2 (hr) |
EP (1) | EP1542668B1 (hr) |
JP (1) | JP4729306B2 (hr) |
KR (1) | KR101043866B1 (hr) |
CN (1) | CN100335047C (hr) |
AR (2) | AR040887A1 (hr) |
AT (1) | ATE428423T1 (hr) |
AU (1) | AU2003269965B2 (hr) |
BR (1) | BR0313602A (hr) |
CA (1) | CA2495864C (hr) |
CY (1) | CY1110331T1 (hr) |
DE (1) | DE60327225D1 (hr) |
DK (1) | DK1542668T3 (hr) |
ES (1) | ES2322953T3 (hr) |
GE (1) | GEP20063996B (hr) |
HR (1) | HRP20050149B1 (hr) |
IL (1) | IL166623A (hr) |
IS (1) | IS2878B (hr) |
MX (1) | MXPA05001865A (hr) |
MY (1) | MY140793A (hr) |
NO (1) | NO333458B1 (hr) |
NZ (1) | NZ537995A (hr) |
PE (1) | PE20040895A1 (hr) |
PL (1) | PL212428B1 (hr) |
PT (1) | PT1542668E (hr) |
RS (1) | RS51903B (hr) |
RU (1) | RU2342931C2 (hr) |
SI (1) | SI1542668T1 (hr) |
TW (1) | TWI307626B (hr) |
UA (1) | UA79984C2 (hr) |
WO (1) | WO2004017897A2 (hr) |
ZA (1) | ZA200501064B (hr) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040170705A1 (en) * | 2001-03-08 | 2004-09-02 | Dusan Miljkovic | Compositions and methods for non-insulin glucose uptake |
CA2495864C (en) * | 2002-08-20 | 2011-09-27 | Bristol-Myers Squibb Company | Aripiprazole complex formulation and method |
ES2315721T5 (es) * | 2003-10-23 | 2012-08-24 | Otsuka Pharmaceutical Co., Ltd. | Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento |
US7714129B2 (en) | 2003-12-16 | 2010-05-11 | Teva Pharmaceutical Industries Ltd. | Methods of preparing anhydrous aripiprazole form II |
TW200529850A (en) * | 2003-12-16 | 2005-09-16 | Teva Pharma | Methods of preparing aripiprazole crystalline forms |
UA89513C2 (uk) * | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Стабільна композиція з наночастинок ралоксифену гідрохлориду |
WO2006113310A2 (en) * | 2005-04-13 | 2006-10-26 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising prostaglandin derivatives |
WO2006133046A2 (en) * | 2005-06-03 | 2006-12-14 | Elan Pharma International, Limited | Nanoparticulate imatinib mesylate formulations |
US20090036406A1 (en) * | 2005-06-13 | 2009-02-05 | Takeda Pharmaceutical Company Limited | Injection |
US20100204178A1 (en) | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
NZ568700A (en) | 2005-11-28 | 2012-03-30 | Marinus Pharmaceuticals | Solid stabilized particulate formulations comprising ganaxolone |
GB0618879D0 (en) | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
CN101322709B (zh) * | 2007-06-12 | 2011-03-02 | 成都康弘药业集团股份有限公司 | 一种含有阿立哌唑的药物组合物及其制备方法 |
LT2170279T (lt) * | 2007-07-31 | 2018-03-12 | Otsuka Pharmaceutical Co., Ltd. | Aripiprazolo suspensijos ir liofilizuotos kompozicijos gamybos būdai |
US8501740B2 (en) * | 2007-10-09 | 2013-08-06 | Board Of Regents, The University Of Texas System | Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors |
EP2268265A2 (en) * | 2008-03-21 | 2011-01-05 | Elan Pharma International Limited | Compositions for site-specific delivery of imatinib and methods of use |
US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
US8431576B2 (en) | 2009-06-25 | 2013-04-30 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
JP5732453B2 (ja) | 2009-06-25 | 2015-06-10 | アルカーメス ファーマ アイルランド リミテッド | Nh酸性化合物のプロドラッグ |
WO2011023796A1 (en) | 2009-08-31 | 2011-03-03 | Abbott Healthcare Products B.V. | Bifeprunox for treating addiction |
KR101125210B1 (ko) * | 2009-09-11 | 2012-03-19 | 주식회사 대웅제약 | 아리피프라졸-벤토나이트-aea 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법 |
US20110140304A1 (en) * | 2009-12-10 | 2011-06-16 | Molecular Imprints, Inc. | Imprint lithography template |
US8592427B2 (en) | 2010-06-24 | 2013-11-26 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
US8383663B2 (en) * | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
IL296695A (en) | 2011-03-18 | 2022-11-01 | Alkermes Pharma Ireland Ltd | Pharmaceutical preparations containing sorbitan esters |
CA2858787C (en) | 2011-12-15 | 2017-11-21 | Alkermes Pharma Ireland Limited | Prodrugs of tertiary amine compounds |
TW201332572A (zh) * | 2011-12-28 | 2013-08-16 | Otsuka Pharma Co Ltd | 具有經取代的β-環糊精之藥物製劑 |
DK2814849T3 (da) | 2012-02-15 | 2020-03-09 | Cydex Pharmaceuticals Inc | Fremgangsmåde til fremstilling af cyclodextrin-derivater |
JP6333802B2 (ja) | 2012-03-19 | 2018-05-30 | アルカームス ファーマ アイルランド リミテッド | ベンジルアルコールを含む医薬組成物 |
CA2867123C (en) | 2012-03-19 | 2021-02-16 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising water-insoluble antipsychotic agents and glycerol esters |
WO2013142198A1 (en) | 2012-03-19 | 2013-09-26 | Alkermes Pharma Ireland Limited | Pharmaaceutical compositions comprising fatty acid esters |
JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
KR101571670B1 (ko) | 2012-08-08 | 2015-11-25 | 주식회사 씨엠지제약 | 아리피프라졸을 포함하는 경구용 속용 필름 제제 |
NZ730571A (en) | 2012-09-19 | 2018-12-21 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions having improved storage stability |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
GR1008186B (el) | 2013-04-22 | 2014-05-08 | "Φαρματεν Α.Β.Ε.Ε.", | Φαρμακευτικο σκευασμα περιεχον ενα ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου |
JP6203682B2 (ja) * | 2013-07-10 | 2017-09-27 | 共和薬品工業株式会社 | アリピプラゾール含有水性液剤 |
US10525057B2 (en) | 2013-09-24 | 2020-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
US20150086408A1 (en) * | 2013-09-26 | 2015-03-26 | General Electric Company | Method of manufacturing a component and thermal management process |
EP3086793B1 (en) | 2013-12-24 | 2022-05-11 | Virginia Commonwealth University | Use of oxygenated cholesterol sulfates (ocs) for the treatment of kidney dysfunction |
GR1008442B (el) | 2014-01-16 | 2015-03-05 | "Φαρματεν Α.Β.Ε.Ε.", | Φαρμακευτικο σκευασμα περιεχον αριπιπραζολη ή αλας αυτης |
EP3119399A4 (en) | 2014-03-20 | 2017-09-27 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
CN105078910B (zh) * | 2015-09-22 | 2018-05-22 | 成都欣捷高新技术开发有限公司 | 一种含有依匹哌唑的冻干口服制剂及其制备方法 |
US10780099B2 (en) | 2015-10-16 | 2020-09-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
CN105616344A (zh) * | 2016-01-06 | 2016-06-01 | 万全万特制药江苏有限公司 | 阿立哌唑注射液及其制备方法 |
AU2017305239C1 (en) * | 2016-08-02 | 2022-08-18 | Durect Corporation | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
KR20230050474A (ko) | 2016-08-11 | 2023-04-14 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
CA3043979A1 (en) | 2016-11-18 | 2018-05-24 | Aicuris Anti-Infective Cures Gmbh | Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions |
US11033506B2 (en) | 2017-11-21 | 2021-06-15 | Sekisui Chemical Co., Ltd. | External skin preparation comprising a core-shell structure |
US11273158B2 (en) | 2018-03-05 | 2022-03-15 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
JP2022543837A (ja) | 2019-08-05 | 2022-10-14 | マリナス ファーマシューティカルズ, インコーポレイテッド | てんかん重積状態の治療に使用するためのガナキソロン |
JP2023503928A (ja) | 2019-12-06 | 2023-02-01 | マリナス ファーマシューティカルズ, インコーポレイテッド | 結節性硬化症の治療での使用のためのガナキソロン |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
JP2893175B2 (ja) * | 1988-10-31 | 1999-05-17 | 大塚製薬株式会社 | カルボスチリル誘導体 |
US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
JP2608788B2 (ja) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神分裂病治療剤 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
IT1263831B (it) | 1993-01-29 | 1996-09-04 | Paolo Chiesi | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina |
JPH07165616A (ja) * | 1993-12-09 | 1995-06-27 | Hisamitsu Pharmaceut Co Inc | シクロデキストリンの複合組成物及び複合化法 |
US5646131A (en) | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
IT1269578B (it) | 1994-04-22 | 1997-04-08 | Chiesi Farma Spa | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base. |
UA57734C2 (uk) | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
JP4012994B2 (ja) | 1996-05-08 | 2007-11-28 | 大塚製薬株式会社 | 抗不安薬 |
JPH10194996A (ja) | 1996-12-25 | 1998-07-28 | Janssen Pharmaceut Nv | アシル化シクロデキストリン含有製薬組成物 |
GB9713149D0 (en) | 1997-06-21 | 1997-08-27 | Pfizer Ltd | Pharmaceutical formulations |
GB9915231D0 (en) | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
CA2311734C (en) | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
MY129350A (en) * | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
AR033485A1 (es) * | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
SE0200301D0 (sv) * | 2002-02-01 | 2002-02-01 | Axon Biochemicals Bv | Thio-carbostyril derivative |
CA2495864C (en) * | 2002-08-20 | 2011-09-27 | Bristol-Myers Squibb Company | Aripiprazole complex formulation and method |
KR20050071611A (ko) | 2002-10-25 | 2005-07-07 | 화이자 프로덕츠 인코포레이티드 | 현탁액 형태의 아릴헤테로환 활성제의 저장 제형 |
-
2003
- 2003-08-14 CA CA2495864A patent/CA2495864C/en not_active Expired - Fee Related
- 2003-08-14 DK DK03751859T patent/DK1542668T3/da active
- 2003-08-14 BR BR0313602-7A patent/BR0313602A/pt not_active Application Discontinuation
- 2003-08-14 PT PT03751859T patent/PT1542668E/pt unknown
- 2003-08-14 AT AT03751859T patent/ATE428423T1/de active
- 2003-08-14 RS YU20050118A patent/RS51903B/sr unknown
- 2003-08-14 AU AU2003269965A patent/AU2003269965B2/en not_active Ceased
- 2003-08-14 EP EP03751859A patent/EP1542668B1/en not_active Expired - Lifetime
- 2003-08-14 JP JP2004531017A patent/JP4729306B2/ja not_active Expired - Fee Related
- 2003-08-14 CN CNB038195534A patent/CN100335047C/zh not_active Expired - Fee Related
- 2003-08-14 US US10/642,366 patent/US7115587B2/en active Active
- 2003-08-14 DE DE60327225T patent/DE60327225D1/de not_active Expired - Lifetime
- 2003-08-14 UA UAA200502492A patent/UA79984C2/uk unknown
- 2003-08-14 GE GEAP8703A patent/GEP20063996B/en unknown
- 2003-08-14 NZ NZ537995A patent/NZ537995A/en not_active IP Right Cessation
- 2003-08-14 SI SI200331586T patent/SI1542668T1/sl unknown
- 2003-08-14 MX MXPA05001865A patent/MXPA05001865A/es active IP Right Grant
- 2003-08-14 RU RU2005107471/15A patent/RU2342931C2/ru not_active IP Right Cessation
- 2003-08-14 TW TW092122407A patent/TWI307626B/zh not_active IP Right Cessation
- 2003-08-14 ES ES03751859T patent/ES2322953T3/es not_active Expired - Lifetime
- 2003-08-14 PL PL374798A patent/PL212428B1/pl unknown
- 2003-08-14 KR KR1020057002789A patent/KR101043866B1/ko active IP Right Grant
- 2003-08-14 WO PCT/US2003/025573 patent/WO2004017897A2/en active Application Filing
- 2003-08-15 MY MYPI20033103A patent/MY140793A/en unknown
- 2003-08-19 AR AR20030102990A patent/AR040887A1/es not_active Application Discontinuation
- 2003-08-20 PE PE2003000843A patent/PE20040895A1/es not_active Application Discontinuation
-
2005
- 2005-02-01 IL IL166623A patent/IL166623A/en active IP Right Grant
- 2005-02-04 ZA ZA200501064A patent/ZA200501064B/xx unknown
- 2005-02-08 NO NO20050661A patent/NO333458B1/no not_active IP Right Cessation
- 2005-02-16 HR HRP20050149AA patent/HRP20050149B1/hr not_active IP Right Cessation
- 2005-02-18 IS IS7701A patent/IS2878B/is unknown
-
2006
- 2006-06-14 US US11/452,782 patent/US7550445B2/en not_active Expired - Fee Related
-
2009
- 2009-04-02 US US12/417,067 patent/US20090186903A1/en not_active Abandoned
- 2009-07-07 CY CY20091100712T patent/CY1110331T1/el unknown
-
2011
- 2011-03-11 US US13/046,124 patent/US20110160224A1/en not_active Abandoned
- 2011-11-03 US US13/288,077 patent/US20120053145A1/en not_active Abandoned
-
2012
- 2012-10-22 US US13/656,785 patent/US20130045981A1/en not_active Abandoned
-
2013
- 2013-04-29 US US13/872,517 patent/US8999952B2/en not_active Expired - Fee Related
-
2015
- 2015-03-03 US US14/636,283 patent/US20150328335A1/en not_active Abandoned
- 2015-09-28 AR ARP150103114A patent/AR102101A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20050149B1 (hr) | Formulacija aripiprazol kompleksa i postupak | |
ECSP066314A (es) | Derivados piridilo y su uso como agentes terapéuticos | |
ATE547416T1 (de) | Pyrazolylbenzothiazolderivate und deren verwendung als therapeutische mittel | |
ATE496893T1 (de) | Isochinolinonderivate und deren verwendung als medikamente | |
ECSP066311A (es) | Derivados de la piperazina y su uso como agentes terapéuticos | |
NO20060974L (no) | Pyridazinderivater og deres anvendelse som terapeutiske midler | |
BRPI0412851A (pt) | benzamidazóis de n-metila-substituìdos | |
MY141939A (en) | Pyridazine derivatives and their use as therapeutic agents | |
TNSN06034A1 (en) | Pyridazine derivatives and their use as therapeutic agents | |
SV2005002099A (es) | " nuevos compuestos " ref. pc 32096a | |
BR0114576A (pt) | Composto, composição farmacêutica, uso de um composto, método de tratar um estado doentio e processo para preparar um composto | |
BRPI0411743A (pt) | método e composições para tratar doenças relacionadas a amilóides | |
SE9900961D0 (sv) | Novel compounds | |
TW200612930A (en) | Diarylmethyl piperazine derivatives, preparations thereof and uses thereof | |
BRPI0406596A (pt) | Métodos para tratar a dor articular e melhorar o sono utilizando um agonista/antagonista de estrogênio | |
NO20051261L (no) | Morfin-6-glukuronidsalt | |
AU4651700A (en) | Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases | |
BR0211237A (pt) | Uso de derivados de aril (ou heteroaril) azolil-carbinóis para o tratamento de incontinência urinária e composição farmacêutica | |
SE0301699D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
BR0213372A (pt) | Medicamento compreendendo combinação de derivado de traizaespiro[5,5]undecano com inibidor de citocromo p450 isozima 3a4 e/ou inibidor de glocoproteìna-p | |
GT200400134A (es) | Sistemas emulsionantes que contienen derivados de azetidina | |
DE69919597D1 (de) | Topische formulierungen, die hautpenetrations-mittel enthalten, und ihre verwendung | |
SE0301445D0 (sv) | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof | |
BR0316123A (pt) | Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico | |
SE0300104D0 (sv) | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
PPPP | Transfer of rights |
Owner name: OTSUKA PHARMACEUTICAL CO., LTD., JP |
|
B1PR | Patent granted | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20170720 Year of fee payment: 15 |
|
PBON | Lapse due to non-payment of renewal fee |
Effective date: 20180814 |